Board Change • Aug 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Carl Ferenbach was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • May 18
Berenson Acquisition Corp. I announced delayed 10-Q filing On 05/16/2024, Berenson Acquisition Corp. I announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Apr 24
Berenson Acquisition Corp. I Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements On April 17, 2024, Berenson Acquisition Corp. I (the ‘Company’) received an official notice of noncompliance (the ‘NYSE American Notice’) from NYSE Regulation (‘NYSE’) stating that the Company is not in compliance with NYSE American continued listing standards (the ‘Filing Delinquency Notification’) due to the failure to timely file the Company’s Form 10-K for the year ended December 31, 2023 (the ‘Delinquent Report’) by the filing due date of April 16, 2024 (the ‘Filing Delinquency’). The Company is now subject to the procedures and requirements set forth in Section 1007 of the NYSE American Company Guide (the ‘Company Guide’). Within five days of the date of the Filing Delinquency Notification, the Company was required to (a) contact the NYSE to discuss the status of the Delinquent Report and (b) issue a press release disclosing the occurrence of the Filing Delinquency, the reason for the Filing Delinquency and, if known, the anticipated date such Filing Delinquency will be cured via the filing or refiling of the applicable report, as the case may be. The NYSE American Notice has no immediate effect on the listing or trading of the Company’s Class A common stock on NYSE American. During the six-month period from the date of the Filing Delinquency (the ‘Initial Cure Period’), the NYSE will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured. If the Company fails to cure the Filing Delinquency within the Initial Cure Period, the NYSE may, in the NYSE’s sole discretion, allow the Company’s securities to be traded for up to an additional six-month period (the ‘Additional Cure Period’) depending on the Company’s specific circumstances. If the NYSE determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. If the NYSE determines that an Additional Cure Period of up to six months is appropriate and the Company fails to file its Delinquent Report and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence. Notwithstanding the foregoing, however, the NYSE may in its sole discretion decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE believes, in the NYSE’s sole discretion, that continued listing and trading of the Company’s securities on the NYSE is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide. The Company intends to regain compliance with the NYSE American continued listing standards. There can be no assurance that the Company will ultimately regain compliance with all applicable NYSE American listing standards. 
